BR112022005420A2 - Processo para a produção de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metil-morfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina - Google Patents
Processo para a produção de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metil-morfolino)piperidin-1-il)-1h-1,2,4-triazol-3-aminaInfo
- Publication number
- BR112022005420A2 BR112022005420A2 BR112022005420A BR112022005420A BR112022005420A2 BR 112022005420 A2 BR112022005420 A2 BR 112022005420A2 BR 112022005420 A BR112022005420 A BR 112022005420A BR 112022005420 A BR112022005420 A BR 112022005420A BR 112022005420 A2 BR112022005420 A2 BR 112022005420A2
- Authority
- BR
- Brazil
- Prior art keywords
- chlorobenzyl
- triazol
- piperidin
- methyl
- morpholino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
processo para a produção de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metil-morfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina. a presente invenção refere-se a um processo para a síntese de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metilmorfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina em duas formas cristalinas hidratadas e em uma forma cristalina anidrosa. a presente invenção também refere-se a (z)-4-((2s,5s)-5-(4-clorobenzil)-2-metilmorfolino)-n-cianopiperidina-1-carbimidotioato de metila que é um intermediário neste processo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962905494P | 2019-09-25 | 2019-09-25 | |
PL43126919 | 2019-09-25 | ||
PCT/IB2020/058984 WO2021059220A1 (en) | 2019-09-25 | 2020-09-25 | Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amine |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022005420A2 true BR112022005420A2 (pt) | 2022-06-21 |
Family
ID=73139065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022005420A BR112022005420A2 (pt) | 2019-09-25 | 2020-09-25 | Processo para a produção de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metil-morfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina |
Country Status (13)
Country | Link |
---|---|
US (2) | US11746107B2 (pt) |
EP (1) | EP4041726A1 (pt) |
JP (1) | JP2022549863A (pt) |
KR (1) | KR20220069008A (pt) |
CN (1) | CN114466845A (pt) |
AU (1) | AU2020356534A1 (pt) |
BR (1) | BR112022005420A2 (pt) |
CA (1) | CA3155177A1 (pt) |
IL (1) | IL291569A (pt) |
MX (1) | MX2022002881A (pt) |
TW (1) | TWI769532B (pt) |
WO (1) | WO2021059220A1 (pt) |
ZA (1) | ZA202204542B (pt) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2802530B1 (fr) * | 1999-12-17 | 2002-02-22 | Sanofi Synthelabo | Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant |
DE60126785T2 (de) * | 2000-08-08 | 2007-10-25 | Ortho-Mcneil Pharmaceutical, Inc. | Nicht-imidazol aryloxypiperidine als h3 rezeptor liganden |
KR101666293B1 (ko) * | 2012-05-30 | 2016-10-13 | 에프. 호프만-라 로슈 아게 | Pde10 억제제로서 트라이아졸로 화합물 |
SG11201605757SA (en) * | 2013-12-20 | 2016-08-30 | Inst Drug Discovery | Substituted amino triazoles, and methods using same |
PL415073A1 (pl) | 2014-12-19 | 2016-06-20 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków |
GB201513740D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
PL415078A1 (pl) * | 2015-09-04 | 2017-03-13 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków |
BR112022000576A2 (pt) | 2019-07-15 | 2022-05-10 | Oncoarendi Therapeutics Sa | Aminotriazóis substituídos úteis como inibidores de quitinase |
-
2020
- 2020-09-25 CN CN202080067709.7A patent/CN114466845A/zh active Pending
- 2020-09-25 BR BR112022005420A patent/BR112022005420A2/pt unknown
- 2020-09-25 CA CA3155177A patent/CA3155177A1/en active Pending
- 2020-09-25 TW TW109133211A patent/TWI769532B/zh active
- 2020-09-25 US US17/032,232 patent/US11746107B2/en active Active
- 2020-09-25 MX MX2022002881A patent/MX2022002881A/es unknown
- 2020-09-25 EP EP20803247.4A patent/EP4041726A1/en active Pending
- 2020-09-25 AU AU2020356534A patent/AU2020356534A1/en active Pending
- 2020-09-25 JP JP2022519042A patent/JP2022549863A/ja active Pending
- 2020-09-25 KR KR1020227009777A patent/KR20220069008A/ko unknown
- 2020-09-25 WO PCT/IB2020/058984 patent/WO2021059220A1/en unknown
-
2022
- 2022-03-21 IL IL291569A patent/IL291569A/en unknown
- 2022-04-22 ZA ZA2022/04542A patent/ZA202204542B/en unknown
-
2023
- 2023-07-17 US US18/222,679 patent/US20240025889A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4041726A1 (en) | 2022-08-17 |
CN114466845A (zh) | 2022-05-10 |
TWI769532B (zh) | 2022-07-01 |
MX2022002881A (es) | 2022-06-08 |
WO2021059220A1 (en) | 2021-04-01 |
US20240025889A1 (en) | 2024-01-25 |
KR20220069008A (ko) | 2022-05-26 |
AU2020356534A1 (en) | 2022-05-19 |
CA3155177A1 (en) | 2021-04-01 |
TW202126644A (zh) | 2021-07-16 |
JP2022549863A (ja) | 2022-11-29 |
IL291569A (en) | 2022-05-01 |
US20210147401A1 (en) | 2021-05-20 |
ZA202204542B (en) | 2023-01-25 |
US11746107B2 (en) | 2023-09-05 |
TW202237594A (zh) | 2022-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1118475T1 (el) | Αντιοξειδωτικοι ρυθμιστες φλεγμονης: c-17 ομολογοποιημενα παραγωγα ολεανολικου οξεος | |
MA49879A (fr) | Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca | |
CY1116333T1 (el) | Παραγωγα βενζοφουρανιου ως ρυθμιστικα μορια των fxr | |
CO7170165A2 (es) | Fabricación de ácido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acético | |
PE20171738A1 (es) | Proceso para la preparacion de antagonistas del receptor androgeno e intermediarios de los mismos | |
CU20170057A7 (es) | Derivados de feniltriazol sustituido con hidroxialquilo | |
UY38084A (es) | Oxadiazoles fungicidas | |
UA106220C2 (ru) | Полиморфные формы гидрохлоридной соли 3-(1-{3-[5-(1-метилпиперидин-4-илметокси)-пиримидин-2-ил]-бензил}-оксо-1,6-дигидропиридазин-3-ил)-бензонитрила и способ их получения (варианты) | |
TN2015000521A1 (en) | Processes of making and crystalline forms of a mdm2 inhibitor | |
BR112013004624A2 (pt) | "derivados de furopiridina" | |
CY1124381T1 (el) | Παραγωγα οξαδιαζολοπυριδινης για χρηση ως αναστολεις της ο-ακυλο τρανσφερασης της γκρελινης | |
BR112014032229A2 (pt) | método para produção de 4-[5-(piridin-4-il)-1h-1,2,4-triazol-3-il) piridina-2-carbonitrila, e intermediários da mesma | |
UY36574A (es) | Inhibidores de bromodominios | |
NZ595823A (en) | 2,5-disubstituted arylsulfonamide ccr3 antagonists | |
ECSP21067828A (es) | Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada | |
BR112021020508A2 (pt) | Inibidor de jak de 7h-pirrolo[2,3-d]pirimidina | |
IL253601B (en) | (2-5-(r4,s (5'-chloro-2'-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as a neprilysin inhibitor | |
CY1122506T1 (el) | Κρυσταλλικη μορφη της ενωσης (s)-3-{4-[5-(2-κυκλοπεντυλ-6- μεθοξυ- πυριδιν-4- υλ)-[1,2,4]οξαδιαζολ-3- υλ]-2- αιθυλ-6-μεθυλ- φαινοξυ}- προπανο-1,2- διολη | |
BR112022005420A2 (pt) | Processo para a produção de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metil-morfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina | |
ECSP099673A (es) | Formas sólidas de un inhibidor de cinasa raf | |
CR20160165A (es) | Acetato de 4-{4-[(1 e)-4-(2,9- diazaespiro [5.5] undec-2-il) but-1 -en-i -il]-2- metilbencil}-5-(propan-2-il) -1h-pirazol-3-ilo beta-d- glucopiranósido | |
PH12017500123B1 (en) | Crystal of azole benzene derivative | |
TWI849432B (zh) | 製造5-(4-((2s,5s)-5-(4-氯芐基)-2-甲基嗎啉基)哌啶-1-基)-1h-1,2,4-三唑-3-胺的方法 | |
PH12017500492A1 (en) | Crystalline bace inhibitors | |
BR112022003171A2 (pt) | Processo para a síntese de compostos de pirazolidinona |